
## Jeremy Carlier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10216857/publications.pdf Version: 2024-02-01



IEDEMY CADLIED

#	Article	lF	CITATIONS
1	Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology, 2019, 17, 974-989.	2.9	244
2	Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair. Frontiers in Chemistry, 2019, 7, 184.	3.6	60
3	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clinical Chemistry, 2017, 63, 1008-1021.	3.2	48
4	<i>In vitro, in vivo</i> and <i>in silico</i> metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis, 2016, 8, 65-82.	1.5	44
5	Screening approach by ultra-high performance liquid chromatography–tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to forensic toxicology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015. 975. 65-76.	2.3	43
6	25Câ€NBOMe and 25Iâ€NBOMe metabolite studies in human hepatocytes, <i>in vivo</i> mouse and human urine with highâ€resolution mass spectrometry. Drug Testing and Analysis, 2017, 9, 680-698.	2.6	43
7	Consequences of COVID-19 Lockdown on the Misuse and Marketing of Addictive Substances and New Psychoactive Substances. Frontiers in Psychiatry, 2020, 11, 584462.	2.6	40
8	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2017, 15, 682-691.	2.9	39
9	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicology, 2017, 35, 20-32.	2.4	31
10	Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review. Therapeutic Drug Monitoring, 2022, 44, 494-510.	2.0	30
11	A 2017–2019 Update on Acute Intoxications and Fatalities from Illicit Fentanyl and Analogs. Journal of Analytical Toxicology, 2021, 45, 537-554.	2.8	29
12	Quantification of Pregabalin Using Hydrophilic Interaction HPLC-High-Resolution MS in Postmortem Human Samples: Eighteen Case Reports. Journal of Analytical Toxicology, 2014, 38, 143-148.	2.8	27
13	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS Journal, 2017, 19, 568-577.	4.4	25
14	A validated method for quantifying hypoglycin A in whole blood by UHPLC–HRMS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 978-979, 70-77.	2.3	24
15	Drug-facilitated sexual assaults (DFSA): a serious underestimated issue. European Review for Medical and Pharmacological Sciences, 2019, 23, 10577-10587.	0.7	24
16	Fatal Case of a 27â€Yearâ€Old Male After Taking Iboga in Withdrawal Treatment: <scp>GC</scp> â€ <scp>MS</scp> / <scp>MS</scp> Determination of Ibogaine and Ibogamine in Iboga Roots and Postmortem Biological Material. Journal of Forensic Sciences, 2013, 58, 1666-1672.	1.6	23
17	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 27-35.	2.8	21
18	In silico prediction, LC-HRMS/MS analysis, and targeted/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolites. Talanta, 2021, 235, 122740.	5.5	20

JEREMY CARLIER

#	Article	IF	CITATIONS
19	The principal toxic glycosidic steroids in Cerbera manghas L. seeds: Identification of cerberin, neriifolin, tanghinin and deacetyltanghinin by UHPLC–HRMS/MS, quantification by UHPLC–PDA-MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 962, 1-8.	2.3	19
20	Quantification of hypoglycin A in serum using aTRAQ® assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 997, 75-80.	2.3	19
21	Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. Therapeutic Drug Monitoring, 2020, 42, 194-204.	2.0	19
22	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 543-550.	2.5	17
23	Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. Therapeutic Drug Monitoring, 2020, 42, 205-221.	2.0	15
24	A Validated Method for Quantifying Atractyloside and Carboxyatractyloside in Blood by HPLC-HRMS/MS, a Non-Fatal Case of Intoxication with Atractylis gummifera L Journal of Analytical Toxicology, 2014, 38, 619-627.	2.8	11
25	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clinical Chemistry, 2017, 63, 1753-1763.	3.2	11
26	Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects. Pharmaceuticals, 2020, 13, 309.	3.8	11
27	3F-α-pyrrolydinovalerophenone (3F-α-PVP) in vitro human metabolism: Multiple in silico predictions to assist in LC-HRMS/MS analysis and targeted/untargeted data mining. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1193, 123162.	2.3	11
28	Atropine Eye Drops: An Unusual Homicidal Poisoning. Journal of Forensic Sciences, 2014, 59, 859-864.	1.6	10
29	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2018, 36, 304-312.	2.4	10
30	Monitoring Prenatal Exposure to Buprenorphine and Methadone. Therapeutic Drug Monitoring, 2020, 42, 181-193.	2.0	10
31	Pyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte Incubations. International Journal of Molecular Sciences, 2021, 22, 230.	4.1	9
32	In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common "diuretic and masking agent―in doping. Archives of Toxicology, 2022, 96, 1989-2001.	4.2	9
33	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2017, 35, 252-262.	2.4	7
34	Advances in Forensic Toxicology. Current Pharmaceutical Design, 2020, 26, 3779-3780.	1.9	7
35	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2016, 1451, 97-106.	3.7	6
36	CannabinoÃ <sup>-</sup> des de synthèseÂ: méthodes analytiques. Toxicologie Analytique Et Clinique, 2015, 27, 184-194.	0.1	3

#	Article	IF	CITATIONS
37	Intoxication mortelle à l' <i>iboga</i> : quantification de l'ibogaÃ⁻ne et de l'ibogamine dans des racines d' <i>iboga</i> et dans des prélÃ∵vements <i>post-mortem</i> par CPG-SM/SM. Toxicologie Analytique Et Clinique, 2012, 24, 39-47.	5 0.1	2
38	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2016, , .	2.9	1
39	Measurement Uncertainty in Forensic Toxicology. Therapeutic Drug Monitoring, 2020, 42, 653-654.	2.0	0